Why tocilizumab could be an effective treatment for severe COVID-19?

Abstract A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress...

Full description

Bibliographic Details
Published in:Journal of Translational Medicine
Main Authors: Binqing Fu, Xiaoling Xu, Haiming Wei
Format: Article
Language:English
Published: BMC 2020-04-01
Subjects:
COVID-19
SARS-CoV-2
Acute respiratory distress syndrome (ARDS)
Inflammatory storm
IL-6
Tocilizumab
Online Access:http://link.springer.com/article/10.1186/s12967-020-02339-3

Internet

http://link.springer.com/article/10.1186/s12967-020-02339-3

Similar Items